Higher urea-to-albumin ratio is associated with mortality risk in critically ill COVID-19 patients

This study aimed to evaluate the ability of the urea-to-albumin ratio (UAR) to predict mortality in critically ill coronavirus disease 2019 (COVID-19) patients. This retrospective study included adult patients admitted with COVID-19 at two intensive care units (ICUs) at the University Hospital. Seru...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical nutrition ESPEN 2023-08, Vol.56, p.9-12
Hauptverfasser: Rodrigues, Hellen Christina Neves, Silva, Mikaelly Luiz, Mantovani, Milena dos Santos, Silva, Juliana Medeiros da, Domingues, Marielle Fernanda Panelli, Tanni, Suzana Érico, Azevedo, Paula Schmidt, Minicucci, Marcos Ferreira, Buffarah, Marina Nogueira Berbel, Pereira, Amanda Gomes, Costa, Nara Aline
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study aimed to evaluate the ability of the urea-to-albumin ratio (UAR) to predict mortality in critically ill coronavirus disease 2019 (COVID-19) patients. This retrospective study included adult patients admitted with COVID-19 at two intensive care units (ICUs) at the University Hospital. Serum urea and albumin concentrations at ICU admission were used to calculate the UAR. All patients were followed up during hospitalization, and the ICU mortality rate was recorded. Two hundred and eleven patients were evaluated. The mean age was 57.8 ± 15.5 years, and 54% were male. Approximately 84.4% of patients were considered to be at nutritional risk by the NRS 2002, and the median UAR was 18.3 (10.5–34.8). The length of stay in the ICU was 10 (6–16) days, 38.4% of the patients required dialysis, and 64.9% died. Age, male sex, need of hemodialysis, lactate level, and inflammatory parameters were associated with higher mortality. Patients non-survivors had a higher UAR (23.7 [13.6–41.8] vs. 10.9 [8.5–16.8]; p 
ISSN:2405-4577
2405-4577
DOI:10.1016/j.clnesp.2023.04.017